Rock Springs Capital Management’s PTC Therapeutics PTCT Stock Holding History

Rock Springs Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.2M	Buy	162,298 +500	+0.3%	+$36.1K	0.65%	48
2026 Q1	$11M	Buy	161,798 +99,919	+161%	+$7.08M	0.65%	46
2025 Q4	$4.7M	Buy	+61,879	New	+$4.5M	0.24%	70
2015 Q4	–	Sell	-42,960	Closed	-$1.15M	–	123
2015 Q3	$1.15M	Sell	42,960 -40	-0.1%	-$1.71K	0.09%	119
2015 Q2	$2.07M	Buy	43,000 +2,500	+6%	+$146K	0.15%	108
2015 Q1	$2.46M	Buy	+40,500	New	+$2.47M	0.23%	94

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Rock Springs Capital Management's PTCT Position: Q2 2026 in Review

Rock Springs Capital Management increased its PTC Therapeutics (PTCT) stake by 0.31% in Q2 2026, buying an estimated $36.1K and bringing the position to 162,298 shares worth $13.2M. The position accounts for 0.65% of the portfolio, ranked #48.

Rock Springs Capital Management first reported a position in PTCT in Q1 2015 and has held it in 6 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Rock Springs Capital Management held 162,298 shares of PTC Therapeutics worth $13.2M as of Q2 2026.
Rock Springs Capital Management bought 500 PTC Therapeutics shares in Q2 2026, an estimated $36.1K.
PTC Therapeutics made up 0.65% of Rock Springs Capital Management's portfolio in Q2 2026, its #48 holding.
Rock Springs Capital Management first reported a position in PTC Therapeutics in Q1 2015 and has held it in 6 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.